DaVitaMEX:DVA 80 Net Margin % is 5.78% as of Mar. 2026, which is 10% below its 10-year median of 6.40. GuruFocus rates MEX:DVA with a GF Score™ of 80/100 and a GF Value™ of MXN2,736.08 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 668 Healthcare Providers & Services companies, DaVita ranks better than 63.92% on this metric.
Net margin is calculated as Net Income divided by its Revenue. DaVita's Net Income for the
three
months ended in Mar. 2026 was MXN3,562 Mil. DaVita's Revenue for the
three
months ended in Mar. 2026 was MXN61,592 Mil. Therefore, DaVita's net margin for the quarter that ended in Mar. 2026 was 5.78%.
The historical rank and industry rank for DaVita's Net Margin % or its related term are showing as below:
MEX:DVA'
s Net Margin % Range Over the Past 10 Years
Min: 1.4 Med: 6.4 Max: 8.42
Current: 5.65
MEX:DVA's Net Margin % is ranked better than 63.92% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 2.885
vs MEX:DVA: 5.65
DaVita (MEX:DVA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
DaVita Net Margin % Related Terms
DaVita Net Margin % Historical Data
* Premium members only.
The historical data trend for DaVita's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:DVA vs EHC, THC, ENSG: Net Margin % Comparison
For the Medical Care Facilities subindustry, DaVita's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaVita Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaVita's Net Margin % distribution charts can be found below:
* The bar in red indicates where DaVita's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaVita (MEX:DVA) has a Net Margin % of 5.78% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on DaVita and its competitors. This is 10% below median its historical median of 6.40. Over the past decade, DaVita's Net Margin % has ranged from 1.40 to 8.42. According to the industry distribution chart, DaVita ranks #241 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 36.1%.
Is DaVita's Net Margin % too high?
DaVita's current Net Margin % of 5.78% is 10% below median its 10-year median of 6.40. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 8.42. The Healthcare Providers & Services industry median Net Margin % is 2.89. DaVita's value of 5.78% is 100.3% above this industry median. Based on the distribution chart, DaVita ranks #241 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, DaVita has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does DaVita's Net Margin % compare to EHC and THC?
According to the Healthcare Providers & Services industry distribution chart, DaVita ranks #241 out of 668 companies for Net Margin %. This puts DaVita in the upper half of its industry. The industry median Net Margin % is 2.89. DaVita's value of 5.78% is 100.3% above this benchmark. Historically, DaVita's own Net Margin % has ranged from 1.40 to 8.42 over the past decade. While the company's 10-year median is 6.40 vs. the industry median of 2.89, DaVita has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaVita's current Net Margin % of 5.78% is 100.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on DaVita and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaVita's current Net Margin % is 5.78%, which is 10% below median its own 10-year median of 6.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaVita stock overvalued right now?
Based on GuruFocus' analysis, DaVita (MEX:DVA) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN2,736.08, compared to a current price of MXN3,358.09 — trading 22.7% above its estimated fair value. The current Net Margin % is 5.78%, which is 10% below median its 10-year median of 6.40 and 100.3% above the Healthcare Providers & Services industry median of 2.89. DaVita's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For DaVita (MEX:DVA), the current Net Margin % is 5.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaVita (MEX:DVA) Overvalued in 2026?
Based on GuruFocus' analysis, DaVita stock appears to be overvalued.
The current stock price of MXN3,358.09 is trading 22.7% above its estimated GF Value™ of MXN2,736.08.
GuruFocus considers DaVita to be Modestly Overvalued.
Key valuation signals for MEX:DVA:
Net Margin %: 5.78% (10% below median its 10-year median of 6.40)
GF Value™: MXN2,736.08 vs. price of MXN3,358.09 (22.7% above fair value)
Industry Position: 100.3% above the Healthcare Providers & Services median (#241 of 668)
No single metric tells the full story. See the MEX:DVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
80GF Score
Get the complete analysis for MEX:DVA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:DVA has been successfully added to your 
